Which pharmacologic class slows the destruction of joints by disrupting tumor necrosis factor?

Which pharmacologic class slows the destruction of joints by disrupting tumor necrosis factor?

• A. Anti-inflammatory
• B. Antimanic
• C. Antiulcer
• D. Antitumor Necrosis Factor

Answer: (D)

Drugs that block TNF slow joint destruction in inflammatory arthritis by interrupting TNF-α signaling. Tumor necrosis factor-α drives inflammation and promotes cartilage and bone damage, including osteoclast activation and pannus formation. By neutralizing TNF or preventing its interaction with receptors, anti-TNF agents blunt the inflammatory cascade, reduce production of other proinflammatory cytokines, and ultimately protect joint structure. This class includes monoclonal antibodies (such as adalimumab, infliximab, certolizumab) and soluble TNF receptor fusion proteins (such as etanercept, golimumab). Other options don’t specifically interfere with TNF signaling and thus don’t halt the progressive joint destruction seen in inflammatory arthritis.

Drugs that block TNF slow joint destruction in inflammatory arthritis by interrupting TNF-α signaling. Tumor necrosis factor-α drives inflammation and promotes cartilage and bone damage, including osteoclast activation and pannus formation. By neutralizing TNF or preventing its interaction with receptors, anti-TNF agents blunt the inflammatory cascade, reduce production of other proinflammatory cytokines, and ultimately protect joint structure. This class includes monoclonal antibodies (such as adalimumab, infliximab, certolizumab) and soluble TNF receptor fusion proteins (such as etanercept, golimumab). Other options don’t specifically interfere with TNF signaling and thus don’t halt the progressive joint destruction seen in inflammatory arthritis.